Efgartigimod PH20 SC

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis12
14Chronic inflammatory demyelinating polyneuropathy25
35Pemphigus14
IDDisease name (Link within this page)Number of trials
63Idiopathic thrombocytopenic purpura18
162Pemphigoid5

11. Myasthenia gravis


Clinical trials : 332Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 175Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

35. Pemphigus


Clinical trials : 99Drugs : 124 - (DrugBank : 36) / Drug target genes : 23 - Drug target pathways : 169 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 391Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

162. Pemphigoid


Clinical trials : 90Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries